The future is here
CELLEXA GENE THERAPY
Cellastra is piondering
I'm a paragraph. Click here to add your own text and edit me. It's easy.
CELLEXA is a proprietary gene vector suitable for human use
Applied in the wound CELLEXA delivers the genetic code for expression and production of anti scarring peptides at the site of injury
CLX-003 is a formulation for injection after after back surgery (spinal laminectomy) or for prevention of intrabdominal adhesions after abdominal or gynecological surgery.
HOW DOES IT WORK?
CELLLEXA is a formulation of an effective transport vehicle (viral vector)
Programmed with the genetic code for a lactoferrin derived anti-scarring peptide.
Applied on top of he skin or by injection CELLEXA delivers the code to the targeted cells.
IEnables continuous production of anti-scarring peptides in the cells of the wound area for many weeks or months.
THE PEPTIDE DISRUPTS ROOT CAUSES OF SCARRING
CLX-001 is gene therapy to prevent scarring after burn injury..
Applied topically by spray or ointment suitable for larger body surface area.
CXL-002 for prevention of dermal scarring after surgery. Applied as gel before wound closure or injected subcuteneously into the wound area in cosmetically challening areas such as the face, mammoplasty or after C-section..
1. CONTROLS INFLAMMATION
inflammation promotes severe scarring
2. STIMULATES FIBRINOLYSIS
Bottom: Blocked fibrinolysis promotes scarring.
Top: Reduced blocking increases fibrinolysis and scar resolution
3. FIGHTS INFECTION
infections cause inflammation which increases scar formation